HCV Next Current Issue
The following articles appeared in the print edition of HCV Next.
Table of Contents
- 2017: A Year in Transition Michael S. Saag, MD
-
- A Conversation With Robert Gish, MD
- HCV 2016 Timeline
- HCV Experts Discuss Impact of Trump Administration
- New HCV Study Underscores Risk for Human Suffering, Need for Clinician Vigilance Carol L. Brosgart, MD
- Canadian Patients With HCV Often Restricted From DAA Treatment
- Epclusa Most Effective for HCV Genotype 3 vs. Other DAAs
- HCV Reinfection Common in MSM With HIV
- Only 35% of Baby Boomers Diagnosed With HCV in ED Linked to Care
-
- Sovaldi-Based HCV Drugs can Interact Adversely With Common HIV Drug
- SVR Post–Interferon-Based Therapy Reduces, not Eliminates Risk for HCC
- Young Suburban Drug Users Drive 'Second Wave' of HCV Epidemic
- Expanded Access to Syringe Service Programs Needed to Limit HCV, HIV Infections
- FDA Approves Roche’s Cobas MPX Test for use With Cobas 6800/8800 Systems
- Gilead Submits NDA for Investigational Treatment of HCV